Application of the concept synthetic lethality toward anticancer therapy: A promise fulfilled?

Cancer Letters

Volumn 352, Issue 1, 2014, Pages 59-65

  Canaani, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer therapy; Chemical synthetic lethality; Genetic synthetic lethality; Oncogenes; RNAi; Tumor suppressor genes

Indexed keywords

COMPLEMENTARY DNA; FLAP ENDONUCLEASE; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PLATINUM COMPLEX; RAD51 PROTEIN; SHORT HAIRPIN RNA; SINGLE STRANDED DNA; SMALL INTERFERING RNA;

ADVANCED CANCER; BIOLOGICAL MONITORING; BREAST CANCER; BREAST METASTASIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELL DAMAGE; CHEMICAL SYNTHETIC LETHALITY; DNA DAMAGE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG MEGADOSE; DRUG RESEARCH; DRUG SCREENING; ENZYME INHIBITION; FEN1 GENE; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SYNTHETIC LETHALITY; GENOMIC INSTABILITY; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR LIBRARY; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; ONCOGENE C MYB; ONCOGENE K RAS; OVARY CANCER; OVERALL SURVIVAL; PARP1 GENE; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RAD51 GENE; SACCHAROMYCES CEREVISIAE; SHORT SURVEY; SYNTHETIC LETHALITY; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

CANCER THERAPY; CHEMICAL SYNTHETIC LETHALITY; GENETIC SYNTHETIC LETHALITY; ONCOGENES; RNAI; TUMOR SUPPRESSOR GENES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; MUTATION; NEOPLASMS; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES;

EID: 84906064853     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.019     Document Type: Review

References (82)

1. Dobzhansky T. Genetics of natural populations. Xiii. Recombination and variability in populations of drosophila pseudoobscura. Genetics 1946, 31:269-290.
2. Bender A., Pringle J.R. Use of a screen for synthetic lethal and multicopy suppressee mutants to identify two new genes involved in morphogenesis in Saccharomyces cerevisiae. Mol. Cell. Biol. 1991, 11:1295-1305.
3. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 2005, 5:689-698.
4. Kroll E.S., Hyland K.M., Hieter P., Li J.J. Establishing genetic interactions by a synthetic dosage lethality phenotype. Genetics 1996, 143:95-102.
5. Hartwell L., Szankasi P., Roberts C., Murray A., Friend S. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997, 278:1064-1068.
6. van Haaften G., Vastenhouw N.L., Nollen E.A., Plasterk R.H., Tijsterman M. Gene interactions in the DNA damage-response pathway identified by genome-wide RNA-interference analysis of synthetic lethality. Proc. Natl. Acad. Sci. USA 2004, 101:12992-12996.
7. Lucchesi J.C. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster. Genetics 1968, 59:37-44.
8. Simon J.A., Szankasi P., Nguyen D.K., Ludlow C., Dunstan H.M., Roberts C.J., Jensen E.L., Hartwell L.H., Friend S.H. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res. 2000, 60:328-333.
9. Dunstan H.M., Ludlow C., Goehle S., Cronk M., Szankasi P., Evans D.R., Simon J.A., Lamb J.R. Cell-based assays for identification of novel double-strand break-inducing agents. J. Natl. Cancer Inst. 2002, 94:88-94.
10. Tong A.H., Boone C. Synthetic genetic array analysis in Saccharomyces cerevisiae. Methods Mol. Biol. 2005, 313:171-192.
11. Pan X., Yuan D.S., Xiangg D., Wang X., Sookhai-Mahadeo S., Bader J.S., Hieter P., Spencer F., Boeke J.D. A robust toolkit for functional profiling of the yeast genome. Mol. Cell 2004, 16:487-496.
12. Ooi S.L., Pan X., Peyser B.D., Ye P., Meluh P.B., Yuan D.S., Irizarry R.A., Bader J.S., Spencer F.A., Boeke J.D. Global synthetic-lethality analysis and yeast functional profiling. Trends Genet. 2006, 22:56-63.
13. Parsons A.B., Brost R.L., Ding H., Li Z., Zhang C., Sheikh B., Brown G.W., Kane P.M., Hughes T.R., Boone C. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat. Biotechnol. 2004, 22:62-69.
14. Lopez A., Parsons A.B., Nislow C., Giaever G., Boone C. Chemical-genetic approaches for exploring the mode of action of natural products. Prog. Drug Res. 2008, 237:239-271.
15. Stark C., Breitkreutz B.J., Reguly T., Boucher L., Breitkreutz A., Tyers M. BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 2006, 34(Database issue):D535-D539.
16. Chatr-Aryamontri A., Breitkreutz B.J., Heinicke S., Boucher L., Winter A., Stark C., Nixon J., Ramage L., Kolas N., O'Donnell L., Reguly T., Breitkreutz A., Sellam A., Chen D., Chang C., Rust J., Livstone M., Oughtred R., Dolinski K., Tyers M. The BioGRID interaction database: update. Nucleic Acids Res. 2013, 41:D816-D823.
17. McManus K.J., Barrett I.J., Nouhi Y., Hieter P. Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc. Natl. Acad. Sci. USA 2009, 106:3276-3281.
18. van Pel D.M., Barrett I.J., Shimizu Y., Sajesh B.V., Guppy B.J., Pfeifer T., McManus K.J., Hieter P. An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development. PLoS Genet. 2013, 9:e1003254.
19. Stockwell B.R., Haggarty S.J., Schreiber S.L. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chem. Biol. 1999, 6:71-83.
20. Torrance C.J., Agrawal V., Vogelstein B., Kinzler K.W. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat. Biotechnol. 2001, 19:940-945.
21. Simons A.H., Dafni N., Dotan I., Oron Y., Canaani D. Establishment of a chemical synthetic lethality screen in cultured human cells. Genome Res. 2001, 11:266-273.
22. Einav Y., Shistik E., Shenfeld M., Simons A.H., Melton D.W., Canaani D. Replication and episomal maintenance of Epstein-Barr virus-based vectors in mouse embryonal fibroblasts enable synthetic lethality screens. Mol. Cancer Ther. 2003, 2:1121-1128.
23. Capecchi M.R. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat. Rev. Genet. 2005, 6:507-512.
24. Gudkov A.V., Zelnick C.R., Kazarov A.R., Thimmapaya R., Suttle D.P., Beck W.T., Roninson I.B. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc. Natl. Acad. Sci. USA 1993, 90:3231-3235.
25. Simons A.H., Dafni N., Dotan I., Oron Y., Canaani D. Genetic synthetic lethality screen at the single gene level in cultured human cells. Nucleic Acids Res. 2001, 29:e100.
26. Tuschl T. Expanding small RNA interference. Nat. Biotechnol. 2002, 20:446-448.
27. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
28. Paddison P.J., Silva J.M., Conklin D.S., Schlabach M., Li M., Aruleba S., Balija V., O'Shaughnessy A., Gnoj L., Scobie K., Chang K., Westbrook T., Cleary M., Sachidanandam R., McCombie W.R., Elledge S.J., Hannon G.J. A resource for large-scale RNA-interference-based screens in mammals. Nature 2004, 428:427-431.
29. Berns K., Hijmans E.M., Mullenders J., Brummelkamp T.R., Velds A., Heimerikx M., Kerkhoven R.M., Madiredjo M., Nijkamp W., Weigelt B., et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004, 428:431-437.
30. Silva J.M., Li M.Z., Chang K., Ge W., Golding M.C., Rickles R.J., Siolas D., Hu G., Paddison P.J., Schlabach M.R., Sheth N., Bradshaw J., Burchard J., Kulkarni A., Cavet G., Sachidanandam R., McCombie W.R., Cleary M.A., Elledge S.J., Hannon G.J. Second-generation shRNA libraries covering the mouse and human genomes. Nat. Genet. 2005, 37:1281-1288.
31. Iorns E., Lord C.J., Turner N., Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat. Rev. Drug Discov. 2007, 6:556-568.
32. Ngo V.N., Davis R.E., Lamy L., Yu X., Zhao H., Lenz G., LamDave L.T.S., Yang L., Powell J., Staudt L.M. Nature 2006, 441:106-110.
33. Schlabach M.R., Luo J., Solimini N.L., Hu G., Xu Q., Li M.Z., Zhao Z., Smogorzewska A., Sowa M.E., Ang X.L., et al. Cancer proliferation gene discovery through functional genomics. Science 2008, 319:620-624.
34. Luo B., Cheung H.W., Subramanian A., Sharifnia T., Okamoto M., Yang X., Hinkle G., Boehm J.S., Beroukhim R., Weir B.A., Mermel C., Barbie D.A., Awad T., Zhou X., Nguyen T., Piqani B., Li C., Golub T.R., Meyerson M., Hacohen N., Hahn W.C., Lander E.S., Sabatini D.M., Root D.E. Highly parallel identification of essential genes in cancer cells. Proc. Natl. Acad. Sci. USA 2008, 105:20380-20385.
35. Silva J.M., Marran K., Parker J.S., Silva J., Golding M., Schlabach M.R., Elledge S.J., Hannon G.J., Chang K. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 2008, 319:617-620.
36. Boettcher M., Fredebohm J., Moghaddas Gholami A., Hachmo Y., Dotan I., Canaani D., Hoheisel J.D. BMC Genom. 2010, 11:7.
37. Dolma S., Lessnick S.L., Hahn W.C., Stockwell B.R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003, 3:285-296.
38. Yang W.S., Stockwell B.R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 2008, 15:234-245.
39. Luo J., Emanuele M.J., Li D., Creighton C.J., Schlabach M.R., Westbrook T.F., Wong K.K., Elledge S.J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
40. Barbie D.A., Tamayo P., Boehm J.S., Kim S.Y., Moody S.E., Dunn I.F., Schinzel A.C., Sandy P., Meylan E., Scholl C., Fröhling S., Chan E.M., Sos M.L., Michel K., Mermel C., Silver S.J., Weir B.A., Reiling J.H., Sheng Q., Gupta P.B., Wadlow R.C., Le H., Hoersch S., Wittner B.S., Ramaswamy S., Livingston D.M., Sabatini D.M., Meyerson M., Thomas R.K., Lander E.S., Mesirov J.P., Root D.E., Gilliland D.G., Jacks T., Hahn W.C. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
41. Scholl C., Fröhling S., Dunn I.F., Schinzel A.C., Barbie D.A., Kim S.Y., Silver S.J., Tamayo P., Wadlow R.C., Ramaswamy S., Döhner K., Bullinger L., Sandy P., Boehm J.S., Root D.E., Jacks T., Hahn W.C., Gilliland D.G. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834.
42. Beierle E.A., Arujillo T., Nagaram A., Kurenova E.V., Finch R., Ma X., Vella J., Cance W.G., Golubovskaya V.M. N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J. Biol. Chem. 2007, 282:12503-12516.
43. Kessler J.D., Kahle K.T., Sun T., Meerbrey K.L., Schlabach M.R., Schmitt E.M., Skinner S.O., Xu Q., Li M.Z., Hartman Z.C., Rao M., Yu P., Dominguez-Vidana R., Liang A.C., Solimini N.L., Bernardi R.J., Yu B., Hsu T., Golding I., Luo J., Osborne C.K., Creighton C.J., Hilsenbeck S.G., Schiff R., Shaw C.A., Elledge S.J., Westbrook T.F. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012, 335:348-353.
44. Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., Fersht A.R. Proc. Natl. Acad. Sci. USA 2008, 105:10360-10365.
45. Iliopoulos O., Kibel A., Gray S., Kaelin W.G. Tumor suppression by the human von Hippel-Lindau gene product. Nat. Med. 1995, 1:822-826.
46. Turcotte S., Chan D.A., Sutphin P.D., Hay M.P., Denny W.A., Giaccia A.J. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 2008, 14:90-102.
47. Neshat M., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., Sawyers C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/Mtor. Proc. Natl. Acad. Sci. USA 2001, 98:10314-10319.
48. Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., Puc J., Neshat M., Wang H., Yang L., Gibbons J., Frost P., Dreisbach V., Blenis J., Gaciong Z., Fisher P., Sawyers C., Hedrick-Ellenson L., Parsons R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA 2001, 98:10320-10325.
49. Kau T.R., Schroeder F., Ramaswamy S., Wojciechowski C.L., Zhao J.J., Roberts T.M., Clardy J., Sellers W.R., Silver P.A. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003, 4:463-476.
50. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
51. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
52. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
53. Xie L., Gazin C., Park S.M., Zhu L.J., Debily M.-a., Kittler E.L., Zapp M.L., Lapointe D., Gobeil S., Virbasius C.M., Green M.R. A synthetic interaction screen identifies factors selectively required for proliferation and TERT transcription in p53-deficient human cancer cells. PLoS Genet. 2012, 8:e1003151.
54. Ström C.E., Johansson F., Uhlén M., Szigyarto C.A., Erixon K., Helleday T. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res. 2011, 2011(39):3166-3175.
55. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstanding. Mol. Oncol. 2011, 5:387-393.
56. Lord C.J., Ashworth A. The DNA damage response and cancer therapy. Nature 2012, 481:287-294.
57. Papeo G., Casale E., Montagnoli A., Cirla A. PARP inhibitors in cancer therapy: an update. Expert Opin. Ther. Pat. 2013, 23:503-514.
58. Balmaña J., Domchek S.M., Tutt A., Garber J.E. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov. 2011, 1:29-34.
59. Marchetti C., Imperiale L., Gasparri M.L., Palaia I., Pignata S., Boni T., Bellati F., Benedetti Panici P. Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opin. Investig. Drugs 2012, 21:1575-1584.
60. Davar D., Beumer J.H., Hamieh L., Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr. Med. Chem. 2012, 19:3907-3921.
61. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., Ashworth A., Carmichael J., Kaye S.B., Schellens J.H., de Bono J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl. J. Med. 2009, 361:123-134.
62. Fong P.C., Yap T.A., Boss D.S., Carden C.P., Mergui-Roelvink M., Gourley C., Greve De J., Lubinski J., Shanley S., Messiou C., Hern R.A'., Tutt A., Ashworth A., Stone J., Carmichael J., Schellens J.H., de Bono J.S., Kaye S.B. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 2010, 28:2512-2519.
63. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., Friedlander M., Arun B., Loman N., Schmutzler R.K., Wardley A., Mitchell G., Earl H., Wickens M., Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
64. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., Lu K., Schmutzler R.K., Matulonis U., Wickens M., Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
65. Gelmon K.A., Tischkowitz M., Mackay H., Swenerton K., Robidoux A., Tonkin K., Hirte H., Huntsman D., Clemons M., Gilks B., Yerushalmi R., Macpherson E., Carmichael J., Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011, 12:852-861.
66. Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C., Meier W., Shapira-Frommer R., Safra T., Matei D., Macpherson E., Watkins C., Carmichael J., Matulonis U. N Engl. J. Med. 2012, 366:1382-1392.
67. O'Shaughnessy J., Osborne C., Pippen J.E., Yoffe M., Patt D., Rocha C., Koo I.C., Sherman B.M., Bradley C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl. J. Med. 2011, 364:205-214.
68. Patel A.G., De Lorenzo S.B., Flatten K.S., Poirier G.G., Kaufmann S.H. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin. Cancer Res. 2012, 18:1655-1662.
69. Liu X., Shi Y., Maag D.X., Palma J.P., Patterson M.J., Ellis P.A., Surber B.W., Ready D.B., Soni N.B., Ladror U.S., Xu A.J., Iyer R., Harlan J.E., Solomon L.R., Donawho C.K., Penning T.D., Johnson E.F., Shoemaker A.R. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bonafide PARP inhibitor. Clin. Cancer Res. 2012, 18:510-523.
70. Oplustilova L., Wolanin K., Mistrik M., Korinkova G., Simkova D., Bouchal J., Lenobel R., Bartkova J., Lau A., O'Connor M.J., Lukas J., Bartek J. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 2012, 11:3837-3850.
71. Daemen A., Wolf D.M., Korkola J.E., Griffith O.L., Frankum J.R., Brough R., Jakkula L.R., Wang N.J., Natrajan R., Reis-Filho J.S., Lord C.J., Ashworth A., Spellman P.T., Gray J.W., van't Veer L.J. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res. Treat. 2012, 135:505-517.
72. Norquist B., Wurz K.A., Pennil C.C., Garcia R., Gross J., Sakai W., Karlan B.Y., Taniguchi T., Swisher E.M. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 2011, 29:3008-3015.
73. Pettitt S.J., Rehman F.L., Bajrami I., Brough R., Wallberg F., Kozarewa I., Fenwick K., Assiotis I., Chen L., Campbell J., Lord C.J., Ashworth A. A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One 2013, 8:e61520.
74. Mendelsohn J. Personalizing oncology: perspectives and prospects. J. Clin. Oncol. 2013, 31:1904-1911.
75. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
76. Hidalgo M., Bruckheimer E., Rajeshkumar N.V., Garrido-Laguna I., De Oliveira E., Rubio-Viqueira B., Strawn S., Wick M.J., Martell J., Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 2011, 10:1311-1316.
77. Canaani D. Methodological approaches in application of synthetic lethality screening towards anticancer therapy. Br. J. Cancer 2009, 100:1213-1218.
78. J.A. Bittker, M. Weiwer, K. Shimada, W.S. Yang, L. MacPherson, S. Dandapani, B. Munoz, M. Palmer, B.R. Stockwell, S.L. Schreiber, Screen for RAS-selective lethal compounds and VDAC ligands - probe 1, probe reports from the NIH molecular libraries program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US), 2010.
79. Benson J.D., Chen Y.N., Cornell-Kennon S.A., Dorsch M., Kim S., Leszczyniecka M., Sellers W.R., Lengauer C. Validating cancer drug targets. Nature 2006, 441:451-456.
80. Babij C., Zhang Y., Kurzeja R.J., Munzli A., Shehabeldin A., Fernando M., Quon K., Kassner P.D., Ruefli-Brasse A.A., Watson V.J., Fajardo F., Jackson A., Zondlo J., Sun Y., Ellison A.R., Plewa C.A., San Miguel T., Robinson J., McCarter J., Schwandner R., Judd T., Carnahan J. Dussault I, STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res. 2011, 71:5818-5826.
81. Luo T., Masson K., Jaffe J.D., Silkworth W., Ross N.T., Scherer C., Scholl C., Fröhling S., Carr S.A., Schreiber S.L., Stern A.M., Golub T.R. STK33 small-molecule kinase inhibitors do not kill KRAS mutant cancer cells. Proc. Natl. Acad. Sci. USA 2012, 109:2860-2865.
82. Weïwer M., Spoonamore J., Wei J., Guichard B., Ross N.T., Masson K., Silkworth W., Dandapani S., Palmer M., Scherer C.A., Stern A.M., Schreiber S.L., Munoz B. A potent and selective quinoxalinone-based STK33 inhibitor does not show synthetic lethality in KRAS-dependent cells. ACS Med. Chem. Lett. 2012, 3:1034-1038.